|

iparomlimab + tuvonralimab Clinical Trials

2 actively recruiting trials

Also known as: Cohort 13 (iparomlimab + tuvonralimab)

Pipeline

Phase 2: 2

Top Sponsors

  • Peking Union Medical College1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer2
  • LOCALLY ADVANCED CERVICAL CANCERS1
  • Precision Therapy1
  • Salivary Gland Carcinoma1

Other2 trials

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Phase 2
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.